Why Bank of Queensland, Fisher & Paykel, Mayne Pharma, and Medibank Shares Are Rising
Why Bank of Queensland, Fisher & Paykel, Mayne Pharma, and Medibank Shares Are Rising
In afternoon trade, the $S&P/ASX 200 (.XJO.AU)$ is on course to end its winning streak with a small decline. At the time of writing, the benchmark index is down 0.1% to 8,016.4 points.
下午交易时，该$S&P/ASX 200 (.XJO.AU)$ 指数即将结束连胜，略微下跌。撰写时，基准指数下跌0.1%，至8016.4点。
Four ASX shares that are not letting that hold them back are listed below. Here's why they are rising today:
以下列出了四种ASX股票，它们不被持有者拖后腿。以下是它们今天上涨的原因:
The Bank of Queensland share price is up 3% to $6.13. This morning, analysts at Morgans responded positively to news that the bank is restructuring its retail operations. The broker sees positives from the restructure and has upgraded its earnings per share estimates to reflect this. As a result, it has upgraded the regional bank's shares to a hold rating with an improved price target of $6.18.
昆士兰银行股价上涨3%，至6.13美元。今早，摩根大通的分析师对该银行重组零售业务的消息做出积极回应。经纪人认为重组带来了积极影响，并已调高了每股收益的预计值以反映这一点。因此，他们将该区域银行的股票评级提升至持有，并提高了其改良后的目标股价至6.18美元。
The Fisher & Paykel Healthcare share price is up 11% to $32.58. Investors have been buying the medical device company's shares following the release of a guidance update this morning. Fisher & Paykel Healthcare is now expecting its revenue to be between NZ$940 million and NZ$950 million for the first half of FY 2015. The mid-point of this range will be an 18% increase over the prior corresponding period. Management expects this to lead to net profit coming in 44% higher at NZ$150 million to NZ$160 million. It notes that "the year to date has begun strongly across all products and regions."
Fisher & Paykel Healthcare股价上涨11%，至32.58美元。投资者在今天上午发布的指引更新后购买了这家医疗器械公司的股票。Fisher & Paykel Healthcare预计其2015财年上半年的营业收入将在NZ$94000万至NZ$95000万之间。这一区间的中点将比去年同期增长18%。管理层预计这将使净利润增长44%，达到NZ$15000万至NZ$16000万。公司指出，“今年迄今为止，在所有产品和区域都有良好的开局。”
The Mayne Pharma share price is up almost 10% to $4.32. This follows the release of the pharmaceutical company's full year results. Investors appear impressed with the company's significantly improved performance. Mayne Pharma reported revenue up 112% on the prior corresponding period to $388.4 million and gross profit up 162% to $218.8 million. CEO Shawn Patrick O'Brien said "Mayne Pharma has delivered a significant improvement in Group performance, achieving all five key operating metrics including a positive direct contribution from all three business segments and a positive underlying EBITDA in FY24."
Mayne Pharma股价上涨近10%，至4.32美元。这是继制药公司发布全年业绩后的反应。投资者对该公司的表现大为印象深刻。Mayne Pharma报告的营业收入环比增长112%，达到38840万美元，毛利润环比增长162%，达到21880万美元。首席执行官Shawn Patrick O'Brien表示：“Mayne Pharma集团业绩有了显著改善，实现了五个关键运营指标，包括所有三个业务部门的正面直接贡献和正面的基本盈利与折旧前利润。”
The Medibank Private share price is up 3% to $3.94. This may have been driven by a broker note out of UBS this morning. In response to the private health insurer's FY 2024 results, the broker has retained its buy rating with an improved price target of $4.30. UBS was pleased with the results and its claims guidance for the year ahead. In light of this, it continues to see plenty of value in its shares at current levels.
Medibank Private股价上涨3%，至3.94美元。这可能是受到UBS今天发布的经纪商报告的影响。针对该私人医疗保险公司2024财年的业绩，这家经纪商保持了其买入评级，并将其目标股价上调至4.30美元。UBS对这一业绩以及未来一年的索赔指引表示满意。鉴于此，它继续看好该股在目前水平上的价值。